Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Total Current Liabilities (2020 - 2025)

Gain Therapeutics has reported Total Current Liabilities over the past 6 years, most recently at $4.2 million for Q3 2025.

  • Quarterly results put Total Current Liabilities at $4.2 million for Q3 2025, down 9.23% from a year ago — trailing twelve months through Sep 2025 was $4.2 million (down 9.23% YoY), and the annual figure for FY2024 was $3.9 million, down 20.98%.
  • Total Current Liabilities for Q3 2025 was $4.2 million at Gain Therapeutics, down from $5.2 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for GANX hit a ceiling of $6.5 million in Q2 2024 and a floor of $2.3 million in Q1 2021.
  • Median Total Current Liabilities over the past 5 years was $4.3 million (2022), compared with a mean of $4.4 million.
  • Biggest five-year swings in Total Current Liabilities: surged 81.24% in 2022 and later fell 20.98% in 2024.
  • Gain Therapeutics' Total Current Liabilities stood at $2.6 million in 2021, then soared by 61.61% to $4.1 million in 2022, then increased by 19.99% to $4.9 million in 2023, then fell by 20.98% to $3.9 million in 2024, then rose by 6.63% to $4.2 million in 2025.
  • The last three reported values for Total Current Liabilities were $4.2 million (Q3 2025), $5.2 million (Q2 2025), and $5.0 million (Q1 2025) per Business Quant data.